MAC
53
2
REGN
53
-3
DOW
62
2
MKC
38
2
ABBV
48
-5
EOG
62
6
ADBE
44
3
FRT
45
2
VIX
38
-3
BMY
66
-3
BSX
42
2
ORLY
58
8
KO
47
3
PSA
35
15
CCI
39
9
EQR
25
5
TRV
42
5
MAS
34
-4
WM
80
6
CTAS
27
3
MAC
53
2
REGN
53
-3
DOW
62
2
MKC
38
2
ABBV
48
-5
EOG
62
6
ADBE
44
3
FRT
45
2
VIX
38
-3
BMY
66
-3
BSX
42
2
ORLY
58
8
KO
47
3
PSA
35
15
CCI
39
9
EQR
25
5
TRV
42
5
MAS
34
-4
WM
80
6
CTAS
27
3
Financhill
Back

Grace Therapeutics, Inc. 10K Form

Sell
47

GRCE
Grace Therapeutics, Inc.

Last Price:
$5.09
Seasonality Move:
-16.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive GRCE News And Ratings

See the #1 stock for the next 7 days that we like better than GRCE

GRCE Financial Statistics

Sales & Book Value

Annual Sales: $0
Cash Flow: $-2.2M
Price / Cash Flow: 0
Annual Sales: $4.19
Price / Book: 1.28

Profitability

EPS (TTM): -0.36030
Net Income (TTM): $-6M
Gross Margin: $-7K
Return on Equity: -9.64%
Return on Assets: -8.61%

Grace Therapeutics, Inc. Earnings Forecast

Key Grace Therapeutics, Inc. Financial Ratios

  • Per Share Earnings over the last 16 years have been positive in 9 years.

Grace Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: GRCE
Website: gracetx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 14.96
Quick Ratio: 14.54

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 18.78

GRCE Technical Analysis vs Fundamental Analysis

Sell
47
Grace Therapeutics, Inc. (GRCE) is a Sell

Is Grace Therapeutics, Inc. a Buy or a Sell?